Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 6, 2015, Pages 1313-1322

  Luxembourg, Alain ^a   Brown, Darron ^b   Bouchard, Celine ^c   Giuliano, Anna R ^d   Iversen, Ole Erik ^e   Joura, Elmar A ^f   Penny, Mary E ^g   Restrepo, Jaime A ^h   Romaguera, Josefina ⁱ   Maansson, Roger ^a   Moeller, Erin ^a   Ritter, Michael ^a   Chen, Joshua ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^h Centro de Investigation Clinica   (Colombia)

ⁱ UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Dose selection; Formulation; HPV; Immunogenicity; Vaccine

Indexed keywords

PLACEBO; VIRUS LIKE PARTICLE VACCINE; VIRUS ANTIBODY; WART VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MEDICAL RESEARCH; NONHUMAN; PHASE 2 CLINICAL TRIAL; VIROLOGY; VIRUS HEMAGGLUTINATION; VIRUS INFECTION; WART VIRUS; ADOLESCENT; ADULT; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; IMMUNOLOGY; MEDICINAL CHEMISTRY; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; PLACEBOS; TREATMENT OUTCOME; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84940615394     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1012010     Document Type: Article

References (13)

1. Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 2007; 11 Suppl 2: S3-S9; PMID:18162244; http://dx. doi. org/10. 1016/S1201- 9712(07)60015-0
2. Madkan VK, Cook-Norris RH, Steadman MC, Arora A, Mendoza N, Tyring SK. The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol 2007; 157: 228-41; PMID:17553059; http://dx. doi. org/10. 1111/j. 1365-2133. 2007. 07961. x
3. Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 2007; 29: 155-62; PMID:17022088; http://dx. doi. org/10. 1002/hed. 20491
4. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5: F12-3; PMID:23199955; http://dx. doi. org/10. 1016/j. vaccine. 2012. 07. 055
5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Suppl 5: F123-38; PMID:23199956; http://dx. doi. org/10. 1016/j. vaccine. 2012. 04. 108
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56; PMID:20952254; http://dx. doi. org/ 10. 1016/S1470-2045(10)70230-8
7. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7: 38; PMID:23273245; http://dx. doi. org/10. 1186/1750- 9378-7-38
8. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012; 30 Suppl 5: F83-7; PMID:23199968; http://dx. doi. org/ 10. 1016/j. vaccine. 2012. 04. 106
9. Brown D, Muller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine 2014; 32: 5880-7; PMID:25148777; http://dx. doi. org/10. 1016/j. vaccine. 2014. 08. 004
10. Chen J, Gesser R, Luxembourg A. A seamless Phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clinical Trials 2015; 12 1:84-90.
11. Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
12. Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014; 10; PMID:25424920; http://dx. doi. org/10. 4161/hv. 29205
13. Villa LL, Ault K, Giuliano AR, Costa RLR, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24: 5571-83; PMID:16753240; http://dx. doi. org/10. 1016/j. vaccine. 2006. 04. 068